Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Mihnea Popa x
Clear All Modify Search
Catalin Cirstoiu Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Catalin Cirstoiu in
Google Scholar
PubMed
Close
,
Bogdan Cretu Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Bogdan Cretu in
Google Scholar
PubMed
Close
,
Sergiu Iordache Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Sergiu Iordache in
Google Scholar
PubMed
Close
,
Mihnea Popa Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Mihnea Popa in
Google Scholar
PubMed
Close
,
Bogdan Serban Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Bogdan Serban in
Google Scholar
PubMed
Close
, and
Adrian Cursaru Orthopedics and Traumatology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Orthopedics and Traumatology Department, University Emergency Hospital Bucharest, Bucharest, Romania

Search for other papers by Adrian Cursaru in
Google Scholar
PubMed
Close

  • Bone metastases are difficult to treat surgically, necessitating a multidisciplinary approach that must be applied to each patient depending on the specifics of their case.

  • The main indications for surgical treatment are a lack of response to chemotherapy, radiation therapy, hormone therapy, immunotherapy, and bisphosphonates which is defined by persistent pain or tumor progression; the risk of imminent pathological bone fracture; and surgical treatment for single bone metastases.

  • An important aspect of choosing the right treatment for these patients is accurately estimating life expectancy. Improved chemotherapy, postoperative radiation therapy, and sustainable reconstructive modalities will increase the patient’s life expectancy.

  • The surgeon should select the best surgical strategy based on the primary tumor and its characteristics, the presence of single or multiple metastases, age, anatomical location, and the functional resources of the patient.

  • Preventive osteosynthesis, osteosynthesis to stabilize a fracture, resections, and reconstructions are the main surgical options for bone metastases.

  • Resection and reconstruction with a modular prosthesis remain the generally approved surgical option to restore functionality, increase the quality of life, and increase life expectancy.

  • Preoperative embolization is necessary, especially in the case of metastases of renal or thyroid origin. This procedure is extremely important to avoid complications, with a major impact on survival rates.

Open access
Irina-Anca Eremia Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Emergency Medicine, Emergency University Hospital, Bucharest, Romania

Search for other papers by Irina-Anca Eremia in
Google Scholar
PubMed
Close
,
Bogdan Serban Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania

Search for other papers by Bogdan Serban in
Google Scholar
PubMed
Close
,
Mihnea Popa Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania

Search for other papers by Mihnea Popa in
Google Scholar
PubMed
Close
,
Adela Iancu Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Search for other papers by Adela Iancu in
Google Scholar
PubMed
Close
,
Silvia Nica Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Emergency Medicine, Emergency University Hospital, Bucharest, Romania

Search for other papers by Silvia Nica in
Google Scholar
PubMed
Close
, and
Catalin Cirstoiu Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Department of Orthopaedics and Traumatology, Emergency University Hospital Bucharest, Romania

Search for other papers by Catalin Cirstoiu in
Google Scholar
PubMed
Close

  • Renal cell carcinoma (RCC) is a common type of tumor that can develop in the kidney. It is responsible for around one-third of all cases of neoplasms. RCC manifests itself in a variety of distinct subtypes. The most frequent of which is clear cell RCC, followed by papillary and chromophobe RCC.

  • RCC has the potential for metastasis to a variety of organs; nevertheless, bone metastases are one of the most common and potentially fatal complications. These bone metastases are characterized by osteolytic lesions that can result in pathological fractures, hypercalcemia, and other complications, which can ultimately lead to a deterioration in quality of life and an increase morbidity.

  • While nephrectomy remains a foundational treatment for RCC, emerging evidence suggests that targeted therapies, including tyrosine kinase inhibitors and T cell checkpoint inhibitors, may offer effective alternatives, potentially obviating the need for adjuvant nephrectomy in certain cases of metastatic RCC

  • Bone metastases continue to be a difficult complication of RCC, which is why more research is required to enhance patient outcome.

Open access